0
0

Chapter 53. Treatment of Depression

Catherine Bresee, M.S.; Jennifer Gotto, M.D.; Mark Hyman Rapaport, M.D.
DOI: 10.1176/appi.books.9781585623860.433754

Sections

Excerpt

The past 20 years have seen a shift in the way psychiatrists conceptualize depressive disorders. This evolution in our thinking has been stimulated by the results of epidemiological studies and of long-term clinical follow-up studies, investigations of spectrum disorders, advances in biological psychiatry, and results of large clinically focused national trials. In the past, major depressive disorder was viewed as episodic and self-limited. However, longitudinal observations of patients treated for major depressive disorder show that after recovery from an index episode of major depression, patients remain symptomatic about 60% of the remainder of their lives with another episode of major depression, minor depressive disorder, or subsyndromal symptoms of depression (Judd et al. 1998a). Data from the National Institute of Mental Health (NIMH) Collaborative Depression Study demonstrated that the recurrence rates of major depressive disorder are extraordinarily high over time: 60% at 5 years of follow-up, 75% at 10 years, and 87% at 15 years (Keller et al. 1982, 1984, 1992; Kupfer 1991).

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Table Reference Number
TABLE 53–1. Medical conditions often comorbid with major depressive disorder
Table Reference Number
TABLE 53–2. DSM-IV-TR criteria for major depressive episode
Table Reference Number
TABLE 53–3. DSM-IV-TR criteria for melancholic features specifier
Table Reference Number
TABLE 53–4. DSM-IV-TR criteria for 300.4 dysthymic disorder
Table Reference Number
TABLE 53–5. Medications that may cause depression
Table Reference Number
TABLE 53–6. Rating scales for symptoms of depression
Table Reference Number
TABLE 53–7. Antidepressant medications

References

Adams F, Quesada JR, Gutterman JU: Neuropsychiatric manifestations of human leukocyte interferon therapy in patients with cancer. JAMA 252:938–941, 1984
[PubMed]
 
Akiskal HS, Judd LL, Gillin JC, et al: Subthreshold depressions: clinical and polysomnographic validation of dysthymic, residual and masked forms. J Affect Disord 45:53–63, 1997
[PubMed]
 
Allen JJ, Schnyer RN, Chambers AS, et al: Acupuncture for depression: a randomized controlled trial. J Clin Psychiatry 67:1665–1673, 2006
[PubMed]
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition. Washington, DC, American Psychiatric Association, 1980
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision. Washington, DC, American Psychiatric Association, 2000a
 
American Psychiatric Association: Practice guideline for the treatment of patients with major depressive disorder (revision). Am J Psychiatry 157 (4 suppl):1–45, 2000b
 
Amsterdam JD, Maislin G, Winokur A, et al: The oCRH stimulation test before and after clinical recovery from depression. J Affect Disord 14:213–222, 1988
[PubMed]
 
Angst F, Stassen HH, Clayton PJ, et al: Mortality of patients with mood disorders: follow-up over 34–38 years. J Affect Disord 68:167–181, 2002
[PubMed]
 
Angst J, Angst F, Gerber-Werder R, et al: Suicide in 406 mood-disorder patients with and without long-term medication: a 40 to 44 years' follow-up. Arch Suicide Res 9:279–300, 2005
[PubMed]
 
Antunes HK, Stella SG, Santos RF, et al: Depression, anxiety and quality of life scores in seniors after an endurance exercise program. Rev Bras Psiquiatr 27:266–271, 2005
[PubMed]
 
Arana GW, Baldessarini RJ, Ornsteen M: The dexamethasone suppression test for diagnosis and prognosis in psychiatry: commentary and review. Arch Gen Psychiatry 42:1193–1204, 1985
[PubMed]
 
Beck AT, Beamesderfer A: Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 7:151–169, 1974
[PubMed]
 
Beck AT, Rush AJ, Shaw BF, et al: Cognitive Therapy of Depression. New York, Guilford, 1979
 
Beck JS: Cognitive Therapy: Basics and Beyond. New York, Guilford, 1995
 
Beekman AT, Deeg DJ, Braam AW, et al: Consequences of major and minor depression in later life: a study of disability, well-being and service utilization. Psychol Med 27:1397–1409, 1997
[PubMed]
 
Beekman AT, Geerlings SW, Deeg DJ, et al: The natural history of late-life depression: a 6-year prospective study in the community. Arch Gen Psychiatry 59:605–611, 2002
[PubMed]
 
Binder EB, Salyakina D, Lichtner P, et al: Polymorphisms in FKBP5 are associated with increased recurrence of depressive episodes and rapid response to antidepressant treatment. Nat Genet 36:1319–1325, 2004
[PubMed]
 
Borgstrom S, von Eyben FE, Flodgren P, et al: Human leukocyte interferon and cimetidine for metastatic melanoma. N Engl J Med 307:1080–1081, 1982
[PubMed]
 
Bremne JD, Vermetten E: Stress and development: behavioral and biological consequences. Dev Psychopathol 13:473–489, 2001
[PubMed]
 
Brouwer JP, Appelhof BC, van Rossum EF, et al: Prediction of treatment response by HPA-axis and glucocorticoid receptor polymorphisms in major depression. Psychoneuroendocrinology 31:1154–1163, 2006
[PubMed]
 
Brown WA, Shuey I: Response to dexamethasone and subtype of depression. Arch Gen Psychiatry 37:747–751, 1980
[PubMed]
 
Bump GM, Mulsant BH, Pollock BG, et al: Paroxetine versus nortriptyline in the continuation and maintenance treatment of depression in the elderly. Depress Anxiety 13:38–44, 2001
[PubMed]
 
Burt VK, Stein K: Epidemiology of depression throughout the female life cycle. J Clin Psychiatry 63 (suppl 7):9–15, 2002
 
Butler AC, Chapman JE, Forman EM, et al: The empirical status of cognitive-behavioral therapy: a review of meta-analyses. Clin Psychol Rev 26:17–31, 2006
[PubMed]
 
Campbell S, Marriott M, Nahmias C, et al: Lower hippocampal volume in patients suffering from depression: a meta-analysis. Am J Psychiatry 161:598–607, 2004
[PubMed]
 
Cannon DS, Tiffany ST, Coon H, et al: The PHQ-9 as a brief assessment of lifetime major depression. Psychol Assess 19:247–251, 2007
[PubMed]
 
Capuron L, Gumnick JF, Musselman DL, et al: Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 26:643–652, 2002
[PubMed]
 
Carroll BJ: The dexamethasone suppression test for melancholia. Br J Psychiatry 140:292–304, 1982
[PubMed]
 
Carroll BJ, Fielding JM, Blashki TG: Depression rating scales: a critical review. Arch Gen Psychiatry 28:361–366, 1973
[PubMed]
 
Caspi A, Sugden K, Moffitt TE, et al: Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 301:386–389, 2003
[PubMed]
 
Cervilla JA, Molina E, Rivera M, et al: The risk for depression conferred by stressful life events is modified by variation at the serotonin transporter 5HTTLPR genotype: evidence from the Spanish PREDICT-Gene cohort. Mol Psychiatry 12:748–755, 2007
[PubMed]
 
Clayton P, Auster T: Strategies for the prevention and treatment of suicidal behavior. Focus 6:15–21, 2008
 
Conklin SM, Manuck SB, Yao JK, et al: High omega-6 and low omega-3 fatty acids are associated with depressive symptoms and neuroticism. Psychosom Med 69:932–934, 2007
[PubMed]
 
Coppen A, Abou-Saleh M, Milln P, et al: Dexamethasone suppression test in depression and other psychiatric illness. Br J Psychiatry 142:498–504, 1983
[PubMed]
 
Couturier JL: Efficacy of rapid-rate repetitive transcranial magnetic stimulation in the treatment of depression: a systematic review and meta-analysis. J Psychiatry Neurosci 30:83–90, 2005
[PubMed]
 
Cuijpers P, de Graaf R, van Dorsselaer S: Minor depression: risk profiles, functional disability, health care use and risk of developing major depression. J Affect Disord 79:71–79, 2004
[PubMed]
 
de Jong-Meyer R, Hautzinger M, Rudolf GAE, et al: The effectiveness of antidepressants and cognitive-behavioral therapy combined in patients with endogenous depression: results of analyses of variance regarding main and secondary outcome criteria [in German]. Z Klin Psychol 25:93–109, 1996
 
Delgado PL, Charney DS, Price LH, et al: Serotonin function and the mechanism of antidepressant action: reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 47:411–418, 1990
[PubMed]
 
DeRubeis RJ, Gelfand LA, Tang TZ, et al: Medications versus cognitive behavior therapy for severely depressed outpatients: mega-analysis of four randomized comparisons. Am J Psychiatry 156:1007–1013, 1999
[PubMed]
 
DeRubeis RJ, Hollon SD, Amsterdam JD, et al: Cognitive therapy vs medications in the treatment of moderate to severe depression. Arch Gen Psychiatry 62:409–416, 2005
[PubMed]
 
Dimidjian S, Hollon SD, Dobson KS, et al: Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the acute treatment of adults with major depression. J Consult Clin Psychol 74:658–670, 2006
[PubMed]
 
Dombrovski AY, Lenze EJ, Dew MA, et al: Maintenance treatment for old-age depression preserves health-related quality of life: a randomized, controlled trial of paroxetine and interpersonal psychotherapy. J Am Geriatr Soc 55:1325–1332, 2007
[PubMed]
 
Drago S, Bergerone S, Anselmino M, et al: Depression in patients with acute myocardial infarction: influence on autonomic nervous system and prognostic role: results of a five-year follow-up study. Int J Cardiol 115:46–51, 2007
[PubMed]
 
Duman RS: Depression: a case of neuronal life and death? Biol Psychiatry 56:140–145, 2004
[PubMed]
 
Elkin I, Gibbons RD, Shea MT, et al: Initial severity and differential treatment outcome in the National Institute of Mental Health Treatment of Depression Collaborative Research Program. J Consult Clin Psychol 63:841–847, 1995
[PubMed]
 
Elkin I, Shea MT, Watkins JT, et al: National Institute of Mental Health Treatment of Depression Collaborative Research Program: general effectiveness of treatments. Arch Gen Psychiatry 46:971–982; discussion 983, 1989
 
Elovainio M, Jokela M, Kivimaki M, et al: Genetic variants in the DRD2 gene moderate the relationship between stressful life events and depressive symptoms in adults: cardiovascular risk in young Finns study. Psychosom Med 69:391–395, 2007
[PubMed]
 
Endicott J, Nee J: Endicott Work Productivity Scale (EWPS): a new measure to assess treatment effects. Psychopharmacol Bull 33:13–16, 1997
[PubMed]
 
Endicott J, Nee J, Harrison W, et al: Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 29:321–326, 1993
[PubMed]
 
Even C, Schröder CM, Friedman S, et al: Efficacy of light therapy in nonseasonal depression: a systematic review. J Affect Disord 108:11–23, 2007
[PubMed]
 
Fava GA: Well-being therapy: conceptual and technical issues. Psychother Psychosom 68:171–179, 1999
[PubMed]
 
Fava GA, Grandi S, Zielezny M, et al: Cognitive behavioral treatment of residual symptoms in primary major depressive disorder. Am J Psychiatry 151:1295–1299, 1994
[PubMed]
 
Fava GA, Savron G, Grandi S, et al: Cognitive-behavioral management of drug-resistant major depressive disorder. J Clin Psychiatry 58:278–282; quiz 283–284, 1997
 
Fava GA, Ruini C, Rafanelli C, et al: Six-year outcome of cognitive behavior therapy for prevention of recurrent depression. Am J Psychiatry 161:1872–1876, 2004
[PubMed]
 
Fava M, Rush AJ, Trivedi MH, et al: Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) study. Psychiatr Clin North Am 26:457–494, 2003
[PubMed]
 
Fava M, Alpert J, Nierenberg AA, et al: A double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder. J Clin Psychopharmacol 25:441–447, 2005
[PubMed]
 
Feldman G: Cognitive and behavioral therapies for depression: overview, new directions, and practical recommendations for dissemination. Psychiatr Clin North Am 30:39–50, 2007
[PubMed]
 
Fergusson DM, Horwood LJ, Ridder EM, et al: Subthreshold depression in adolescence and mental health outcomes in adulthood. Arch Gen Psychiatry 62:66–72, 2005
[PubMed]
 
Field T, Ironson G, Scafidi F, et al: Massage therapy reduces anxiety and enhances EEG pattern of alertness and math computations. Int J Neurosci 86:197–205, 1996
[PubMed]
 
Fogel J, Eaton WW, Ford DE: Minor depression as a predictor of the first onset of major depressive disorder over a 15-year follow-up. Acta Psychiatr Scand 113:36–43, 2006
[PubMed]
 
Frank E, Kupfer DJ, Perel JM, et al: Three-year outcomes for maintenance therapies in recurrent depression. Arch Gen Psychiatry 47:1093–1099, 1990
[PubMed]
 
Frank E, Kupfer DJ, Wagner EF, et al: Efficacy of interpersonal psychotherapy as a maintenance treatment of recurrent depression: contributing factors. Arch Gen Psychiatry 48:1053–1059, 1991a
 
Frank E, Prien RF, Jarrett RB, et al: Conceptualization and rationale for consensus definitions of terms in major depressive disorder: remission, recovery, relapse, and recurrence. Arch Gen Psychiatry 48:851–855, 1991b
 
Frank E, Kupfer DJ, Buysse DJ, et al: Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression. Am J Psychiatry 164:761–767, 2007
[PubMed]
 
Freis ED: Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med 251:1006–1008, 1954
[PubMed]
 
George MS, Wassermann EM, Williams W A, et al: Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport 6:1853–1856, 1995
[PubMed]
 
George MS, Rush AJ, Marangell LB, et al: A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry 58:364–373, 2005
[PubMed]
 
George MS, Nahas Z, Borckardt JJ, et al: Brain stimulation for the treatment of psychiatric disorders. Curr Opin Psychiatry 20:250–254; discussion 247–249, 2007
 
Gertsik L, Poland RE: Psychoneuroendocrinology, in Textbook of Psychopharmacology. Edited by Schatzberg A, Nemeroff CB. Washington, DC, American Psychiatric Press, 2004, pp 115–129
 
Gibbons JL, McHugh PR: Plasma cortisol in depressive illness. J Psychiatr Res 1:162–171, 1962
[PubMed]
 
Gibbons RD, Hur K, Bhaumik DK, et al: The relationship between antidepressant medication use and rate of suicide. Arch Gen Psychiatry 62:165–172, 2005
[PubMed]
 
Gillespie CF, Nemeroff CB: Hypercortisolemia and depression. Psychosom Med 67 (suppl 1):S26–S28, 2005
 
Ginsberg DL, Schooler NR, Buckley PF, et al: Optimizing treatment of schizophrenia: enhancing affective/cognitive and depressive functioning. CNS Spectr 10:1–13; discussion 14–15, 2005
 
Gispen-de Wied CC, Kok FW, Koppeschaar HP, et al: Stimulation of the pituitary-adrenal system with graded doses of CRH and low dose vasopressin infusion in depressed patients and healthy subjects: a pilot study. Eur Neuropsychopharmacol 3:533–541, 1993
 
Glassman AH, Shapiro PA: Depression and the course of coronary artery disease. Am J Psychiatry 155:4–11, 1998
[PubMed]
 
Gold PW, Loriaux DL, Roy A, et al: Responses to corticotropin-releasing hormone in the hypercortisolism of depression and Cushing's disease: pathophysiologic and diagnostic implications. N Engl J Med 314:1329–1335, 1986
[PubMed]
 
Goldapple K, Segal Z, Garson C, et al: Modulation of cortical-limbic pathways in major depression: treatment-specific effects of cognitive behavior therapy. Arch Gen Psychiatry 61:34–41, 2004
[PubMed]
 
Goldney RD, Fisher LJ, Dal Grande E, et al: Subsyndromal depression: prevalence, use of health services and quality of life in an Australian population. Soc Psychiatry Psychiatr Epidemiol 39:293–298, 2004
[PubMed]
 
Guy W: ECDEU assessment manual for psychopharmacology. Rockville, MD, U.S. Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976
 
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62, 1960
[PubMed]
 
Hamilton M: Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296, 1967
[PubMed]
 
Harris PA: The impact of age, gender, race, and ethnicity on the diagnosis and treatment of depression. J Manag Care Pharm 10 (2 suppl):S2–S7, 2004
 
Hasin DS, Goodwin RD, Stinson FS, et al: Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 62:1097–1106, 2005
[PubMed]
 
Hautzinger M, de Jong-Meyer R, Treiber R, et al: Efficacy of cognitive behavior therapy, pharmacotherapy, and the combination of both in non-melancholic, unipolar depression [in German]. Z Klin Psychol 25:130–145, 1996
 
Heim C, Newport DJ, Heit S, et al: Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. JAMA 284:592–597, 2000
[PubMed]
 
Helmer C, Montagnier D, Pérès K: Descriptive epidemiology and risk factors of depression in the elderly [in French]. Psychol Neuropsychiatr Vieil 2 (suppl 1):S7–S12, 2004
 
Henriksson S, Isacsson G: Increased antidepressant use and fewer suicides in Jämtland county, Sweden, after a primary care educational programme on the treatment of depression. Acta Psychiatr Scand 114:159–167, 2006
[PubMed]
 
Hermens ML, van Hout HP, Terluin B, et al: The prognosis of minor depression in the general population: a systematic review. Gen Hosp Psychiatry 26:453–462, 2004
[PubMed]
 
Hirschfeld RM: The comorbidity of major depression and anxiety disorders: recognition and management in primary care. Prim Care Companion J Clin Psychiatry 3:244–254, 2001
[PubMed]
 
Hirschfeld RM, Klerman GL, Clayton PJ, et al: Personality and depression: empirical findings. Arch Gen Psychiatry 40:993–998, 1983
[PubMed]
 
Hollon SD, DeRubeis RJ, Shelton RC, et al: Prevention of relapse following cognitive therapy vs medications in moderate to severe depression. Arch Gen Psychiatry 62:417–422, 2005
[PubMed]
 
Holsboer F: Neuroendocrinology of mood disorders, in Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York, Raven, 1995, pp 957–971
 
Holsboer F: The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology 23:477–501, 2000
[PubMed]
 
Horowitz A, Reinhardt JP, Kennedy GJ: Major and subthreshold depression among older adults seeking vision rehabilitation services. Am J Geriatr Psychiatry 13:180–187, 2005
[PubMed]
 
Howland RH, Schettler PJ, Rapaport MH, et al: Clinical features and functioning of patients with minor depression. Psychother Psychosom 77:384–389, 2008
[PubMed]
 
Hu XZ, Rush AJ, Charney D, et al: Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 64:783–792, 2007
[PubMed]
 
Hunt SM, McKenna SP: The QLDS: a scale for the measurement of quality of life in depression. Health Policy 22:307–319, 1992
[PubMed]
 
Jacobson NS, Hollon SD: Cognitive-behavior therapy versus pharmacotherapy: now that the jury's returned its verdict, it's time to present the rest of the evidence. J Consult Clin Psychol 64:74–80, 1996
[PubMed]
 
Jacobson NS, Dobson KS, Truax PA, et al: A component analysis of cognitive-behavioral treatment for depression. J Consult Clin Psychol 64:295–304, 1996
[PubMed]
 
Janakiramaiah N, Gangadhar BN, Naga Venkatesha Murthy PJ, et al: Antidepressant efficacy of Sudarshan Kriya Yoga (SKY) in melancholia: a randomized comparison with electroconvulsive therapy (ECT) and imipramine. J Affect Disord 57:255–259, 2000
[PubMed]
 
Joffe H, Hall JE, Soares CN, et al: Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause 9:392–398, 2002
[PubMed]
 
Joyce PR, McKenzie JM, Carter JD, et al: Temperament, character and personality disorders as predictors of response to interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatry 190:503–508, 2007
[PubMed]
 
Judd LL, Akiskal HS: Delineating the longitudinal structure of depressive illness: beyond clinical subtypes and duration thresholds. Pharmacopsychiatry 33:3–7, 2000
[PubMed]
 
Judd LL, Akiskal HS: The clinical and public health relevance of current research on subthreshold depressive symptoms to elderly patients. Am J Geriatr Psychiatry 10:233–238, 2002
[PubMed]
 
Judd LL, Rapaport MH, Paulus MP, et al: Subsyndromal symptomatic depression: a new mood disorder? J Clin Psychiatry 55 (suppl):18–28, 1994
 
Judd LL, Paulus MP, Wells KB, et al: Socioeconomic burden of subsyndromal depressive symptoms and major depression in a sample of the general population. Am J Psychiatry 153:1411–1417, 1996
[PubMed]
 
Judd LL, Akiskal HS, Paulus MP: The role and clinical significance of subsyndromal depressive symptoms (SSD) in unipolar major depressive disorder. J Affect Disord 45:5–17; discussion 17–18, 1997
 
Judd LL, Akiskal HS, Maser JD, et al: A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 55:694–700, 1998a
 
Judd LL, Akiskal HS, Maser JD, et al: Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 50(2–3):97–108, 1998b
 
Judd LL, Akiskal HS, Zeller PJ, et al: Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 57:375–380, 2000
[PubMed]
 
Judd LL, Rapaport MH, Yonkers KA, et al: Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorder. Am J Psychiatry 161:1864–1871, 2004
[PubMed]
 
Kabat-Zinn J: Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress, Pain, and Illness. New York, Delacorte Press, 1990
 
Kaplan RM: Quality of life assessment for cost/utility studies in cancer. Cancer Treat Rev 19 (suppl A):85–96, 1993
 
Kaplan RM, Anderson JP: An integrated approach to quality of life assessments: the general health policy model, in Quality of Life in Clinical Studies. Edited by Spilker B. New York, Raven, 1990, pp 131–149
 
Keller MB, Berndt ER: Depression treatment: a lifelong commitment? Psychopharmacol Bull 36 (suppl 2):133–141, 2002
 
Keller MB, Shapiro RW, Lavori PW, et al: Relapse in major depressive disorder: analysis with the life table. Arch Gen Psychiatry 39:911–915, 1982
[PubMed]
 
Keller MB, Klerman GL, Lavori PW, et al: Long-term outcome of episodes of major depression: clinical and public health significance. JAMA 252:788–792, 1984
[PubMed]
 
Keller MB, Lavori PW, Mueller TI, et al: Time to recovery, chronicity, and levels of psychopathology in major depression: a 5-year prospective follow-up of 431 subjects. Arch Gen Psychiatry 49:809–816, 1992
[PubMed]
 
Keller MB, McCullough JP, Klein DN, et al: A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 342:1462–1470, 2000
[PubMed]
 
Keller MB, Trivedi MH, Thase ME, et al: The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: outcomes from the acute and continuation phases. Biol Psychiatry 62:1371–1379, 2007a
 
Keller MB, Trivedi MH, Thase ME, et al: The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) Study: outcomes from the 2-year and combined maintenance phases. J Clin Psychiatry 68:1246–1256, 2007b
 
Kendler KS, Kuhn JW, Vittum J, et al: The interaction of stressful life events and a serotonin transporter polymorphism in the prediction of episodes of major depression: a replication. Arch Gen Psychiatry 62:529–535, 2005
[PubMed]
 
Kennedy SH, Evans KR, Kruger S, et al: Changes in regional brain glucose metabolism measured with positron emission tomography after paroxetine treatment of major depression. Am J Psychiatry 158:899–905, 2001
[PubMed]
 
Kessler RC, McGonagle KA, Zhao S, et al: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 51:8–19, 1994
[PubMed]
 
Kessler RC, Zhao S, Blazer DG, et al: Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord 45(1–2):19–30, 1997
[PubMed]
 
Khan A, Brodhead AE, Kolts RL: Relative sensitivity of the Montgomery-Asberg depression rating scale, the Hamilton depression rating scale and the Clinical Global Impressions rating scale in antidepressant clinical trials: a replication analysis. Int Clin Psychopharmacol 19:157–160, 2004
[PubMed]
 
Kling MA, Alesci S, Csako G, et al: Sustained low-grade pro-inflammatory state in unmedicated, remitted women with major depressive disorder as evidenced by elevated serum levels of the acute phase proteins C-reactive protein and serum amyloid A. Biol Psychiatry 62:309–313, 2007
[PubMed]
 
Kripke DF: Photoperiodic mechanisms for depression and its treatment, in Biological Psychiatry. Edited by Perris C, Struwe G, Jansson B. Elsevier-North Holland Biomedical Press, 1981, pp 1249–1252
 
Kroenke K, Spitzer RL, Williams JB: The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16:606–613, 2001
[PubMed]
 
Kupfer DJ: Long-term treatment of depression. J Clin Psychiatry 52 (suppl):28–34, 1991
 
Kupfer DJ, Frank E, Perel JM, et al: Five-year outcome for maintenance therapies in recurrent depression. Arch Gen Psychiatry 49:769–773, 1992
[PubMed]
 
Kuyken W, Dalgleish T, Holden ER: Advances in cognitive-behavioural therapy for unipolar depression. Can J Psychiatry 52:5–13, 2007
[PubMed]
 
Laje G, Paddock S, Manji H, et al: Genetic markers of suicidal ideation emerging during citalopram treatment of major depression. Am J Psychiatry 164:1530–1538, 2007
[PubMed]
 
Leon AC, Shear MK, Portera L, et al: Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 27:78–82, 1992
[PubMed]
 
Lewy AJ, Sack RL: Light therapy and psychiatry. Proc Soc Exp Biol Med. 183:11–18, 1986
[PubMed]
 
Liu Z, Zhu F, Wang G, et al: Association study of corticotropin-releasing hormone receptor1 gene polymorphisms and antidepressant response in major depressive disorders. Neurosci Lett 414:155–158, 2007
[PubMed]
 
Lopez AD, Murray CC: The global burden of disease, 1990–2020. Nat Med 4:1241–1243, 1998
[PubMed]
 
Lopez AD, Mathers CD, Ezzati M, et al: Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet 367:1747–1757, 2006
[PubMed]
 
Luty SE, Carter JD, McKenzie JM, et al: Randomised controlled trial of interpersonal psychotherapy and cognitive-behavioural therapy for depression. Br J Psychiatry 190:496–502, 2007
[PubMed]
 
Maddux RE, Rapaport MH: Psychopharmacology and psychotherapy of subsyndromal depressions, in Handbook of Chronic Depression: Diagnosis and Therapeutic Management. Edited by Alpert JE, Fava M. New York, Informa Healthcare, 2004, pp 183–206
 
Maes M: Evidence for an immune response in major depression: a review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19:11–38, 1995
[PubMed]
 
Maes M: Major depression and activation of the inflammatory response system, in Cytokines, Stress, and Depression. Edited by Dantzer R, Wollman EE, Yirmiya R. New York, Kluwer Academic/Plenum, 1999, pp 25–46
 
Maes M, Meltzer HY, Bosmans E, et al: Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 34:301–309, 1995
[PubMed]
 
Mayberg HS, Brannan SK, Tekell JL, et al: Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol Psychiatry 48:830–843, 2000
[PubMed]
 
Mayberg HS, Lozano AM, Voon V, et al: Deep brain stimulation for treatment-resistant depression. Neuron 45:651–660, 2005
[PubMed]
 
McCullough JP: Treatment for Chronic Depression: Cognitive Behavioral Analysis System of Psychotherapy. New York, Guilford, 2000
 
McCusker J, Cole M, Dufouil C, et al: The prevalence and correlates of major and minor depression in older medical inpatients. J Am Geriatr Soc 53:1344–1353, 2005
[PubMed]
 
McPherson S, Cairns P, Carlyle J, et al: The effectiveness of psychological treatments for treatment-resistant depression: a systematic review. Acta Psychiatr Scand 111:331–340, 2005
[PubMed]
 
Melfi CA, Chawla AJ, Croghan TW, et al: The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry 55:1128–1132, 1998
[PubMed]
 
Meyers CA: Mood and cognitive disorders in cancer patients receiving cytokine therapy, in Cytokines, Stress, and Depression. Edited by Dantzer R, Wollman EE, Yirmiya R. New York, Kluwer Academic/Plenum, 1999, pp 75–81
 
Miller IW, Norman WH, Keitner GI, et al: Cognitive-behavioral treatment of depressed inpatients. Behav Ther 20:25–47, 1989a
 
Miller IW, Norman WH, Keitner GI: Cognitive-behavioral treatment of depressed inpatients: six- and twelve-month follow-up. Am J Psychiatry 146:1274–1279, 1989b
 
Miller IW, Keitner GI, Schatzberg AF, et al: The treatment of chronic depression, part 3: psychosocial functioning before and after treatment with sertraline or imipramine. J Clin Psychiatry 59:608–619, 1998
[PubMed]
 
Mischoulon D, Fava M: Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidence. Am J Clin Nutr 76:1158S–1161S, 2002
 
Montgomery SA, Åsberg M: A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389, 1979
[PubMed]
 
Mundt JC, Marks IM, Shear MK, et al: The Work and Social Adjustment Scale: a simple measure of impairment in functioning. Br J Psychiatry 180:461–464, 2002
[PubMed]
 
Murck H, Fava M, Alpert J, et al: Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placebo. Int J Neuropsychopharmacol 8:215–221, 2005
[PubMed]
 
Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet 349:1498–1504, 1997
[PubMed]
 
Musselman DL, Lawson DH, Gumnick JF, et al: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344:961–966, 2001
[PubMed]
 
Nemeroff CB, Vale WW: The neurobiology of depression: inroads to treatment and new drug discovery. J Clin Psychiatry 66 (suppl 7):5–13, 2005
 
Nemeroff CB, Heim CM, Thase ME, et al: Differential responses to psychotherapy versus pharmacotherapy in patients with chronic forms of major depression and childhood trauma. Proc Natl Acad Sci U S A 100:14293–14296, 2003
[PubMed]
 
Nunes EV: Substance abuse and depression. Paper presented at the annual meeting of the American Psychiatric Association, San Francisco, CA, May 2003
 
Olfson M, Fireman B, Weissman MM, et al: Mental disorders and disability among patients in a primary care group practice. Am J Psychiatry 154:1734–1740, 1997
[PubMed]
 
O'Reardon JP, Solvason HB, Janicak PG, et al: Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 62:1208–1216, 2007
[PubMed]
 
Osei-Tutu KB, Campagna PD: The effects of short- vs long-bout exercise on mood, VO2max, and percent body fat. Prev Med 40:92–98, 2005
[PubMed]
 
Otto MW, Smits JAJ, Reese HE: Combined psychotherapy and pharmacotherapy for mood and anxiety disorders in adults: review and analysis. Clinical Psychology: Science and Practice 12:72–86, 2005
 
Papakostas GI, Shelton RC, Smith J, et al: Augmentation of antidepressants with atypical antipsychotic medications for treatment-resistant major depressive disorder: a meta-analysis. J Clin Psychiatry 68:826–831, 2007
[PubMed]
 
Papiol S, Arias B, Gasto C, et al: Genetic variability at HPA axis in major depression and clinical response to antidepressant treatment. J Affect Disord 104:83–90, 2007
[PubMed]
 
Paykel ES, Ramana R, Cooper Z, et al: Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25:1171–1180, 1995
[PubMed]
 
Paykel ES, Cooper Z, Ramana R, et al: Life events, social support and marital relationships in the outcome of severe depression. Psychol Med 26:121–133, 1996
[PubMed]
 
Paykel ES, Scott J, Teasdale JD, et al: Prevention of relapse in residual depression by cognitive therapy: a controlled trial. Arch Gen Psychiatry 56:829–835, 1999
[PubMed]
 
Perlis RH: Pharmacogenetic studies of antidepressant response: how far from the clinic? Psychiatr Clin North Am 30:125–138, 2007
[PubMed]
 
Petty F, Kramer GL, Hendrickse W: GABA and depression, in Biology of Depressive Disorders, Part A: A Systems Perspective. Edited by Mann JJ, Kupler DJ. New York, Plenum, 1993, pp 79–108
 
Pilkington K, Kirkwood G, Rampes H, et al: Yoga for depression: the research evidence. J Affect Disord 89:13–24, 2005
[PubMed]
 
Pittenger C, Sanacora G, Krystal JH: The NMDA receptor as a therapeutic target in major depressive disorder. CNS Neurol Disord Drug Targets 6:101–115, 2007
[PubMed]
 
Potter GG, Steffens DC: Contribution of depression to cognitive impairment and dementia in older adults. Neurologist 13:105–117, 2007
[PubMed]
 
Prien RF, Kupfer DJ, Mansky PA, et al: Drug therapy in the prevention of recurrences in unipolar and bipolar affective disorders: report of the NIMH Collaborative Study Group comparing lithium carbonate, imipramine, and a lithium carbonate-imipramine combination. Arch Gen Psychiatry 41:1096–1104, 1984
[PubMed]
 
Raadsheer FC, Hoogendijk WJ, Stam FC, et al: Increased numbers of corticotropin-releasing hormone expressing neurons in the hypothalamic paraventricular nucleus of depressed patients. Neuroendocrinology 60:436–444, 1994
[PubMed]
 
Rapaport MH, Judd LL: Minor depressive disorder and subsyndromal depressive symptoms: functional impairment and response to treatment. J Affect Disord 48:227–232, 1998
[PubMed]
 
Rapaport MH, Tipp JE, Schuckit MA: A comparison of ICD-10 and DSM-III-R criteria for substance abuse and dependence. Am J Drug Alcohol Abuse 19:143–151, 1993
[PubMed]
 
Rapaport MH, Judd LL, Schettler PJ, et al: A descriptive analysis of minor depression. Am J Psychiatry 159:637–643, 2002
[PubMed]
 
Rapaport MH, Clary C, Fayyad R, et al: Quality-of-life impairment in depressive and anxiety disorders. Am J Psychiatry 162:1171–1178, 2005
[PubMed]
 
Rapaport MH, Gharabawi GM, Canuso CM, et al: Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31:2505–2513, 2006
[PubMed]
 
Reinherz HZ, Paradis AD, Giaconia RM, et al: Childhood and adolescent predictors of major depression in the transition to adulthood. Am J Psychiatry 160:2141–2147, 2003
[PubMed]
 
Reynolds CF 3rd, Frank E, Perel JM, et al: Nortriptyline and interpersonal psychotherapy as maintenance therapies for recurrent major depression: a randomized controlled trial in patients older than 59 years. JAMA 281:39–45, 1999
[PubMed]
 
Rich CL, Isacsson G: Suicide and antidepressants in south Alabama: evidence for improved treatment of depression. J Affect Disord 45:135–142, 1997
[PubMed]
 
Rieckmann N, Burg MM, Gerin W, et al: Depression vulnerabilities in patients with different levels of depressive symptoms after acute coronary syndromes. Psychother Psychosom 75:353–361, 2006
[PubMed]
 
Roche Pharmaceuticals: AmpliChip® CYP450 Test. Available at: http://www.roche.com/products/product-details.htm?type=product&id=17. Accessed December 2008.
 
Rubin RT, Poland RE, Lesser IM, et al: Neuroendocrine aspects of primary endogenous depression, I: cortisol secretory dynamics in patients and matched controls. Arch Gen Psychiatry 44:328–336, 1987
[PubMed]
 
Ruhe HG, Mason NS, Schene AH: Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies. Mol Psychiatry 12:331–359, 2007
[PubMed]
 
Rush AJ, Giles DE, Schlesser MA, et al: The Inventory for Depressive Symptomatology (IDS): preliminary findings. Psychiatry Res 18:65–87, 1986
[PubMed]
 
Rush AJ, Trivedi MH, Ibrahim HM, et al: The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry 54:573–583, 2003
[PubMed]
 
Rush AJ, Fava M, Wisniewski SR, et al: Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design. Control Clin Trials 25:119–142, 2004
[PubMed]
 
Rush AJ, Bernstein IH, Trivedi MH, et al: An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a Sequenced Treatment Alternatives to Relieve Depression trial report. Biol Psychiatry 59:493–501, 2006a
 
Rush AJ, Trivedi MH, Wisniewski SR, et al: Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 163:1905–1917, 2006b
 
Rush AJ, Trivedi MH, Wisniewski SR, et al: Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231–1242, 2006c
 
Ryff CD: Happiness is everything, or is it?: explorations on the meaning of psychological well-being. J Pers Soc Psychol 57:1069–1081, 1989
 
Sachar EJ, Hellman L, Fukushima DK, et al: Cortisol production in depressive illness: a clinical and biochemical clarification. Arch Gen Psychiatry 23:289–298, 1970
[PubMed]
 
Sackeim HA, Brannan SK, Rush AJ, et al: Durability of antidepressant response to vagus nerve stimulation (VNS). Int J Neuropsychopharmacol 10:817–826, 2007
[PubMed]
 
Schiepers OJ, Wichers MC, Maes M: Cytokines and major depression. Prog Neuropsychopharmacol Biol Psychiatry 29:201–217, 2005
[PubMed]
 
Schlaepfer TE, Frick C, Zobel A, et al: Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychol Med 38:651–661, 2008
[PubMed]
 
Schramm E, van Calker D, Dykierek P, et al: An intensive treatment program of interpersonal psychotherapy plus pharmacotherapy for depressed inpatients: acute and long-term results. Am J Psychiatry 164:768–777, 2007
[PubMed]
 
Segal Z, Teasdale J, Williams M: Mindfulness-Based Cognitive Therapy for Depression. New York, Guilford, 2002
 
Sequeira A, Gwadry FG, Ffrench-Mullen JM, et al: Implication of SSAT by gene expression and genetic variation in suicide and major depression. Arch Gen Psychiatry 63:35–48, 2006
[PubMed]
 
Shaw BF, Elkin I, Yamaguchi J, et al: Therapist competence ratings in relation to clinical outcome in cognitive therapy of depression. J Consult Clin Psychol 67:837–846, 1999
[PubMed]
 
Sluzewska A, Rybakowski J, Bosmans E, et al: Indicators of immune activation in major depression. Psychiatry Res 64:161–167, 1996
[PubMed]
 
Smit F, Cuijpers P, Oostenbrink J, et al: Costs of nine common mental disorders: implications for curative and preventive psychiatry. J Ment Health Policy Econ 9:193–200, 2006
[PubMed]
 
Smith CA, Hay PP: Acupuncture for depression. Cochrane Database Syst Rev (2):CD004046, 2005
 
Smits K, Smits L, Peeters F, et al: Serotonin transporter polymorphisms and the occurrence of adverse events during treatment with selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 22:137–143, 2007a
 
Smits KM, Smits LJ, Schouten JS, et al: Does pretreatment testing for serotonin transporter polymorphisms lead to earlier effects of drug treatment in patients with major depression? A decision-analytic model. Clin Ther 29:691–702, 2007b
 
Søndergård L, Kvist K, Lopez AG, et al: Temporal changes in suicide rates for persons treated and not treated with antidepressants in Denmark during 1995–1999. Acta Psychiatr Scand 114:168–176, 2006
[PubMed]
 
Stahl LA, Begg DP, Weisinger RS, et al: The role of omega-3 fatty acids in mood disorders. Curr Opin Investig Drugs 9:57–64, 2008
[PubMed]
 
Stewart WF, Ricci JA, Chee E, et al: Cost of lost productive work time among US workers with depression. JAMA 289:3135–3144, 2003
[PubMed]
 
Tabuse H, Kalali A, Azuma H, et al: The new GRID Hamilton Rating Scale for Depression demonstrates excellent inter-rater reliability for inexperienced and experienced raters before and after training. Psychiatry Res 153:61–67, 2007
[PubMed]
 
Thase ME: Redefining antidepressant efficacy toward long-term recovery. J Clin Psychiatry 60 (suppl 6):15–19, 1999
 
Thase ME, Friedman ES, Biggs MM, et al: Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D report. Am J Psychiatry 164:739–752, 2007
[PubMed]
 
Trivedi MH, Rush AJ, Ibrahim HM, et al: The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med 34:73–82, 2004
[PubMed]
 
Trivedi MH, Fava M, Wisniewski SR, et al: Medication augmentation after the failure of SSRIs for depression. N Engl J Med 354:1243–1252, 2006a
 
Trivedi MH, Greer TL, Grannemann BD, et al: Exercise as an augmentation strategy for treatment of major depression. J Psychiatr Pract 12:205–213, 2006b
 
Trivedi MH, Greer TL, Grannemann BD, et al: TREAD: TReatment with Exercise Augmentation for Depression: study rationale and design. Clin Trials 3:291–305, 2006c
 
Trivedi MH, Rush AJ, Wisniewski SR, et al: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 163:28–40, 2006d
 
UK ECT Review Group: Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis. Lancet 361:799–808, 2003
 
U.S. Department of Health and Human Services: National strategy for suicide prevention. A collaborative effort of SAMHSA, CDC, NIH, HRSA, HIS. 2001. Available at: http://mentalhealth.samhsa.gov/suicideprevention/elderly.asp. Accessed December 2, 2008.
 
van Rossum EF, Binder EB, Majer M, et al: Polymorphisms of the glucocorticoid receptor gene and major depression. Biol Psychiatry 59:681–688, 2006
 
Videbech P, Ravnkilde B: Hippocampal volume and depression: a meta-analysis of MRI studies. Am J Psychiatry 161:1957–1966, 2004
[PubMed]
 
Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Med Care 30:473–483, 1992
[PubMed]
 
Ware J Jr, Kosinski M, Keller SD: A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220–233, 1996
[PubMed]
 
Warner-Schmidt JL, Duman RS: Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus 16:239–249, 2006
[PubMed]
 
Weissman MM, Klerman GL: Sex differences and the epidemiology of depression. Arch Gen Psychiatry 34:98–111, 1977
[PubMed]
 
Weissman MM, Bland RC, Canino GJ, et al: Cross-national epidemiology of major depression and bipolar disorder. JAMA 276:293–299, 1996
[PubMed]
 
Wells KB, Stewart A, Hays RD, et al: The functioning and well-being of depressed patients: results from the Medical Outcomes Study. JAMA 262:914–919, 1989
[PubMed]
 
Westrin A, Lam RW: Long-term and preventative treatment for seasonal affective disorder. CNS Drugs 21:901–909, 2007
[PubMed]
 
Williams JB: A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 45:742–747, 1988
[PubMed]
 
Wisniewski SR, Fava M, Trivedi MH, et al: Acceptability of second-step treatments to depressed outpatients: a STAR*D report. Am J Psychiatry 164:753–760, 2007
[PubMed]
 
Zimmerman M, Thongy T: How often do SSRIs and other new-generation antidepressants lose their effect during continuation treatment? Evidence suggesting the rate of true tachyphylaxis during continuation treatment is low. J Clin Psychiatry 68:1271–1276, 2007
[PubMed]
 
Zung WWK: A self-rating depression scale. Arch Gen Psychiatry 12:371–379, 1965
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
A significant National Institute of Mental Health (NIMH)—funded study, Sequenced Treatment Alternatives to Relieve Depression (STAR*D), was an evidence-based approach to the treatment of major depressive disorder. Which of the following are findings from this study?
2.
Vulnerability factors for the development of depression include all of the following except
3.
Major depressive disorder is highly comorbid with selected psychiatric disorders. For which of the following disorders is the rate of comorbid depression highest?
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 31.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 18.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 23.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 24.  >
Topic Collections
Psychiatric News
PubMed Articles
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation